Question. Does treating H. Pylori reduce the incidence of gastric cancer? Study. Randomised placebo-controlled trial. Main results. At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, n= 7; placebo: 1.35%, n =11; p =0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment n =0; placebo n =6; p =0.02) but there was no difference among people with precancerous lesions (n =7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk. Authors' conclusions. Incidence of gastric cancer was similar between H. pylori eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.
All Science Journal Classification (ASJC) codes